Download PDF
Pharmacopsychiatry 2007; 40(5): 173-182
DOI: 10.1055/s-2007-985881
Review

© Georg Thieme Verlag KG Stuttgart · New York

A Review of the Assessment of Antidepressant-Induced Sexual Dysfunction used In Randomized, Controlled Clinical Trials

E. M. Haberfellner 1 , 2
  • 1Rehabilitation Center for Psychosocial Health, Bad Hall, Austria
  • 2Paracelsus Medical University, Salzburg, Austria
Further Information

Publication History

received 08.01.2007 revised 08.06.2007

accepted 03.07.2007

Publication Date:
17 September 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Sexual dysfunction is a well-known side effect of many antidepressants. Obtaining accurate data on sexual dysfunction from clinical trials is difficult because of methodological problems. This paper reviews the assessment and reporting of sexual dysfunction in clinical trials.

Methods: 79 randomized double-blind studies comparing efficacy and tolerability of new antidepressants in major depressive disorder were included. Papers were searched for the methodology of adverse event assessment and for any information on treatment-emergent sexual dysfunction.

Results: 74.7% of the reviewed studies relied on spontaneous reports, 17.7% on non-specific side-effect checklists and only 7.6% on specific assessment instruments. 31.6% of the reviewed studies reported sexual dysfunction as a side effect of antidepressant treatment. Detailed information on the kind of sexual dysfunction based on DSM-IV terminology was provided by only 10.1% of the papers. More recent studies published in 2000 or later reported sexual dysfunction more often (48.6%) than studies published before the year 2000 (18.2%).

Discussion: The specific assessment of sexual dysfunction should be adopted as a part of the safety and tolerability assessment in clinical trials. Future research is needed to elaborate the advantages and disadvantages of the available instruments for the assessment of sexual dysfunction.

References

  • 1 Baldwin DS. Sexual dysfunction associated with antidepressant drugs.  Expert Opin Drug Saf. 2004;  3 457-470
    CrossrefPubMedGoogle Scholar
  • 2 Balon R. The effects of antidepressants on human sexuality: Diagnosis and management update 2004.  Primary Psychiatry. 2004;  11 58-66
    PubMedGoogle Scholar
  • 3 Behnke K, Sogaard J, Martin S, Bauml J, Ravindran AV, Agren H. et al . Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.  J Clin Psychopharmacol. 2003;  23 358-364
    CrossrefPubMedGoogle Scholar
  • 4 Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France.  Curr Med Res Opin. 2003;  19 114-124
    CrossrefPubMedGoogle Scholar
  • 5 Clayton AH, Owens JE, MacGarvey EL. Assessment of paroxetine induced sexual dysfunction using the Changes in Sexual Functioning Questionnaire.  Psychopharmacol Bull. 1995;  31 397-413
    PubMedGoogle Scholar
  • 6 Clayton AH, MacGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability and validity.  Psychopharmacol Bull. 1997;  33 731-745
    PubMedGoogle Scholar
  • 7 Cohen S, Kühn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Rothermundt M, Signerski J, Sträter B, Teusch L, Weig W, Welling A, Westheide J, Huber TJ. Sexual impairment in psychiatric inpatients: focus on depression.  Pharmacopsychiatry. 2007;  40 58-63
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Cunningham LA, Venlafaxine XR. 208 Study Group . Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression.  Ann Clin Psychiatry. 1997;  9 157-164
    CrossrefPubMedGoogle Scholar
  • 9 Demyttenaere K, Fruyt J De, Sienaert P. Psychotropics and sexuality.  Int Clin Psychopharmacol. 1998;  13 ((Suppl 6)) 35-41
    PubMedGoogle Scholar
  • 10 Derogatis LR, Maelisaratos N. The DSFI: a multidimensional measure of sexual functioning.  J Sex Marital Ther. 1979;  5 244-281
    PubMedGoogle Scholar
  • 11 Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.  J Clin Psychiatry. 1996;  57 ((Suppl 2)) 53-62
    PubMedGoogle Scholar
  • 12 Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review.  J Clin Psychiatry. 2001;  62 ((Suppl 3)) 22-34
    PubMedGoogle Scholar
  • 13 Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study.  Pharmacopsychiatry. 2006;  39 66-75
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN. et al . Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.  Biol Psychiatry. 2003;  54 806-817
    CrossrefPubMedGoogle Scholar
  • 15 Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.  J Clin Psychiatry. 2002;  63 225-231
    PubMedGoogle Scholar
  • 16 Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.  J Clin Psychopharmacol. 2004;  24 389-399
    PubMedGoogle Scholar
  • 17 Haberfellner EM. Role of receptor binding profiles in antidepressant induced sexual dysfunction.  J Clin Psychiatry. 2002;  63 168
    PubMedGoogle Scholar
  • 18 Haberfellner EM, Rittmannsberger H. Spontanous remission of SSRI-induced orgasm delay.  Pharmacopsychiatry. 2004;  37 127-130
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Harrison WM, Rabkin JG, Ehrhardt AA, Stewart JW. et al . Effects of antidepressant medication on sexual function: A controlled study.  J Clin Psychopharmacol. 1986;  6 144-149
    PubMedGoogle Scholar
  • 20 Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics.  Pharmacopsychiat. 2006;  39 47-51
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression.  J Affect Disord. 1999;  56 201-208
    PubMedGoogle Scholar
  • 22 Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.  J Clin Psychiatry. 2000;  61 276-281
    CrossrefPubMedGoogle Scholar
  • 23 Labbate LA, Lare SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire.  Psychother Psychosom. 2001;  70 221-225
    CrossrefPubMedGoogle Scholar
  • 24 Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.  J Clin Psychiatry. 2005;  66 100-106
    PubMedGoogle Scholar
  • 25 Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management.  J Psychopharmacol. 1997;  11 72-82
    PubMedGoogle Scholar
  • 26 Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU-side effect rating scale.  Acta Psychiatr Scand. 1987;  76 ((Suppl 334)) 1-100
    PubMedGoogle Scholar
  • 27 MacGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, MacKnight KM. et al . The Arizona Sexual Experience Scale (ASEX): reliability and validity.  J Sex Marital Ther. 2000;  26 25-40
    PubMedGoogle Scholar
  • 28 Mehtonen OP, Sogaard J, Roponen P, Behnke K. Venlafaxine 631 Study Group . Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder.  J Clin Psychiatry. 2000;  61 95-100
    PubMedGoogle Scholar
  • 29 Modell JG, Katholi CR, Modell JD, Palma RL De. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.  Clin Pharmacol Ther. 1997;  61 476-487
    PubMedGoogle Scholar
  • 30 Montejo-González AL, Llorca G, Izquirdo JA, Ledesma A, Bousono M, Calcedo A. et al . SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and desriptive clinical study of 344 patients.  J Sex Marital Ther. 1997;  23 176-194
    CrossrefPubMedGoogle Scholar
  • 31 Montejo AL, Llorca G, Izquirdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients.  J Clin Psychiatry. 2001;  62 ((Suppl 3)) 10-21
    Google Scholar
  • 32 Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction.  J Affect Disord. 2002;  69 119-140
    CrossrefPubMedGoogle Scholar
  • 33 Muller MJ, Ruof J, Graf-Morgenstern M, Porst H, Benkert O. Quality of partnership in patients with erectile dysfunction after sildenafil treatment.  Pharmacopsychiatry. 2001;  34 91-95
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Musa MN, Staneluis JM. Adverse events of fluoxetine: postmarketing compared with premarketing clinical trials.  J Clin Psychiatry. 2000;  61 874
    PubMedGoogle Scholar
  • 35 Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research.  J Clin Psychopharmacol. 1992;  12 3-10
    PubMedGoogle Scholar
  • 36 Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review.  J Clin Psychopharmacol. 1999;  19 67-85
    CrossrefPubMedGoogle Scholar
  • 37 Rothschild AJ. Sexual side effects of antidepressants.  J Clin Psychiatry. 2000;  61 ((Suppl 11)) 28-36
    PubMedGoogle Scholar
  • 38 Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: Systematic review of randomized controlled trials.  J Affect Disord. 2005;  88 241-254
    Google Scholar
  • 39 Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.  Can J Psychiatry. 2002;  47 174-180
    PubMedGoogle Scholar
  • 40 Versiani M, Maehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.  J Clin Psychiatry. 1999;  60 400-406
    PubMedGoogle Scholar
  • 41 Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.  J Clin Psychopharmacol. 2002;  20 28-34
    PubMedGoogle Scholar
  • 42 Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ. Comparative Efficacy Antidepressants Study Group . Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.  CNS Drugs. 2005;  19 137-146
    CrossrefPubMedGoogle Scholar
  • 43 Wade A, Crawford GM, Angus M, Wilson R, Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.  Int Clin Psychopharmacol. 2003;  18 133-141
    PubMedGoogle Scholar
  • 44 Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR. et al . Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.  J Clin Psychiatry. 1993;  54 459-465
    PubMedGoogle Scholar
  • 45 Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction.  Acta Psychiatr Scand. 2006;  114 384-397
    Google Scholar
  • 46 Williams VSL, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries. A cross-sectional patient survey.  J Clin Psychiatry. 2006;  67 204-210
    CrossrefPubMedGoogle Scholar
  • 47 Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory.  Psychopharmacol Bull. 1997;  33 755-760
    PubMedGoogle Scholar
  • 48 Zajecka J, Dunner DL, Gelenberg AJ, Hirschfeld RM, Kornstein SG, Ninan PT. et al . Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.  J Clin Psychiatry. 2002;  63 709-716
    PubMedGoogle Scholar

Correspondence

E. M. HaberfellnerMD 

Rehabilitation Center for Psychosocial Health

Pro Mente Upper Austria

Paracelsus Medical University Salzburg

Parkstraße 5

4540 Bad Hall

Austria

Phone: +43/7258/2959 29 11

Fax: +43/7258/2959 25 5

Email: haberfellnerem@promenteooe.at

      >